A Study of LY2623091 in Participants With High Blood Pressure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 304 participants.

Also called NCT02194465

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 304 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02194465
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02194465. Randomized; double masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2020-06-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2623091 in Participants With High Blood Pressure
Condition
Primary Hypertension
Intervention (Drug)
LY2623091
Intervention (Drug)
Tadalafil
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02194465
Content hash
8c37d300d537ac772e40a5af60e4e0711ee91828aa1412ae278eaf333cade7c5